Projected Growth of Global Lupus Nephritis Market to USD 4.08 Billion by 2034#India#Pune#targeted_therapies#Biologics#Lupus_Nephritis_Market
Projected Growth of Global Lupus Nephritis Market to USD 4.08 Billion by 2034
The global lupus nephritis market is set to grow from USD 1.96 billion in 2025 to USD 4.08 billion by 2034, driven by rising disease burden and advances in treatment.
third-news.com
September 22, 2026 at 9:57 PM
Projected Growth of Global Lupus Nephritis Market to USD 4.08 Billion by 2034#India#Pune#targeted_therapies#Biologics#Lupus_Nephritis_Market
Transforming Hypertrophic Cardiomyopathy Treatment and Market Trends for the Next Decade#USA#Las_Vegas#targeted_therapies#Market_Insights#Hypertrophic_Cardiomyopathy
Transforming Hypertrophic Cardiomyopathy Treatment and Market Trends for the Next Decade
Explore the future of hypertrophic cardiomyopathy with the rise of targeted therapies, paving the way for improved patient outcomes and market expansion until 2036.
third-news.com
August 17, 2026 at 2:40 PM
Transforming Hypertrophic Cardiomyopathy Treatment and Market Trends for the Next Decade#USA#Las_Vegas#targeted_therapies#Market_Insights#Hypertrophic_Cardiomyopathy
Elephas Enhances elive™ Platform for Measuring Cytotoxicity in Targeted Therapies#USA#Madison#targeted_therapies#Elephas_Biosciences#elive_platform
Elephas Enhances elive™ Platform for Measuring Cytotoxicity in Targeted Therapies
Elephas Biosciences announces new data showcasing its elive™ platform's capability to evaluate cytotoxicity in targeted therapies, marking a significant advancement in cancer treatment.
third-news.com
July 24, 2026 at 1:03 PM
Elephas Enhances elive™ Platform for Measuring Cytotoxicity in Targeted Therapies#USA#Madison#targeted_therapies#Elephas_Biosciences#elive_platform
ALK Inhibitors Market Forecasts a 4% CAGR Growth Through 2036 with New Therapies#None#oncology#targeted_therapies#ALK_Inhibitors
ALK Inhibitors Market Forecasts a 4% CAGR Growth Through 2036 with New Therapies
The ALK inhibitors market is poised for significant growth at a 4% CAGR from 2026 to 2036, driven by advancements in precision oncology and emerging therapies.
third-news.com
July 23, 2026 at 2:55 PM
ALK Inhibitors Market Forecasts a 4% CAGR Growth Through 2036 with New Therapies#None#oncology#targeted_therapies#ALK_Inhibitors
EGFR Inhibitors Market: Projected Growth of 7.9% CAGR Driven by Innovative Treatments#None#targeted_therapies#EGFR_inhibitors#Oncology_Treatments
EGFR Inhibitors Market: Projected Growth of 7.9% CAGR Driven by Innovative Treatments
The EGFR inhibitors market shows promising forecasts with a 7.9% CAGR from 2026-2036, fueled by the launch of innovative therapies and rising adoption.
third-news.com
June 15, 2026 at 4:34 PM
EGFR Inhibitors Market: Projected Growth of 7.9% CAGR Driven by Innovative Treatments#None#targeted_therapies#EGFR_inhibitors#Oncology_Treatments
Global Oncology Drug Market Expected to Surpass $335 Billion by 2033 with Growth at 7.2% CAGR#None#Cancer_Treatments#targeted_therapies#Oncology_Drugs
Global Oncology Drug Market Expected to Surpass $335 Billion by 2033 with Growth at 7.2% CAGR
A new report projects the oncology/cancer drugs market to reach $335.2 billion by 2033, driven by increased awareness and demand for targeted treatments.
third-news.com
February 10, 2026 at 5:06 PM
Global Oncology Drug Market Expected to Surpass $335 Billion by 2033 with Growth at 7.2% CAGR#None#Cancer_Treatments#targeted_therapies#Oncology_Drugs
Nuvalent Set to Showcase Breakthrough Oncology Research at Upcoming Healthcare Conference#United_States#Cambridge#Cancer_Research#Nuvalent#targeted_therapies
Nuvalent Set to Showcase Breakthrough Oncology Research at Upcoming Healthcare Conference
Nuvalent, Inc., a leader in targeted cancer therapies, will participate in the Piper Sandler Annual Healthcare Conference, highlighting advancements in cutting-edge oncology research.
third-news.com
November 26, 2025 at 11:39 AM
Nuvalent Set to Showcase Breakthrough Oncology Research at Upcoming Healthcare Conference#United_States#Cambridge#Cancer_Research#Nuvalent#targeted_therapies
KLKB1 Inhibitors Market Poised for Remarkable Growth by 2034 Thanks to Innovative Therapies#None#targeted_therapies#Hereditary_Angioedema#KLKB1_Inhibitors
KLKB1 Inhibitors Market Poised for Remarkable Growth by 2034 Thanks to Innovative Therapies
The KLKB1 inhibitors market is set for substantial growth by 2034, propelled by new therapies and a focus on personalized medicine in treating rare diseases.
third-news.com
November 19, 2025 at 10:41 PM
KLKB1 Inhibitors Market Poised for Remarkable Growth by 2034 Thanks to Innovative Therapies#None#targeted_therapies#Hereditary_Angioedema#KLKB1_Inhibitors
Basal Cell Nevus Syndrome Market Growth Accelerates with Innovative Treatments and Research Advances#United_States#Las_Vegas#targeted_therapies#Basal_Cell_Nevus#Gorlin_Syndrome
Basal Cell Nevus Syndrome Market Growth Accelerates with Innovative Treatments and Research Advances
The basal cell nevus syndrome market is set for significant growth driven by greater awareness, novel therapies, and ongoing clinical research initiatives. This landscape is rapidly evolving.
third-news.com
October 27, 2025 at 9:41 PM
Basal Cell Nevus Syndrome Market Growth Accelerates with Innovative Treatments and Research Advances#United_States#Las_Vegas#targeted_therapies#Basal_Cell_Nevus#Gorlin_Syndrome
Projected Growth of Glomerulonephritis Market Driven by Advancements in Targeted Therapies#United_States#Las_Vegas#Clinical_Trials#targeted_therapies#glomerulonephritis
Projected Growth of Glomerulonephritis Market Driven by Advancements in Targeted Therapies
The glomerulonephritis market is expected to expand significantly by 2034, fueled by the rising incidence of chronic kidney diseases and innovative therapies.
third-news.com
October 22, 2025 at 9:39 PM
Projected Growth of Glomerulonephritis Market Driven by Advancements in Targeted Therapies#United_States#Las_Vegas#Clinical_Trials#targeted_therapies#glomerulonephritis
Global Nanomedicine Market Set to Surge to $389.52 Billion by 2033 Driven by Targeted Therapies and Drug Delivery Advancements#United_States#Austin#targeted_therapies#Drug_Delivery#nanomedicine
Global Nanomedicine Market Set to Surge to $389.52 Billion by 2033 Driven by Targeted Therapies and Drug Delivery Advancements
The global nanomedicine market is projected to skyrocket to $389.52 billion by 2033 driven by demand for advanced therapies and drug delivery systems, expanding innovation across the industry.
third-news.com
October 13, 2025 at 3:22 PM
Global Nanomedicine Market Set to Surge to $389.52 Billion by 2033 Driven by Targeted Therapies and Drug Delivery Advancements#United_States#Austin#targeted_therapies#Drug_Delivery#nanomedicine
Strengthening the Future of Platinum-Resistant Ovarian Cancer Treatment: Emerging Strategies and Market Dynamics#United_States#Las_Vegas#Clinical_Trials#targeted_therapies#Ovarian_Cancer
Strengthening the Future of Platinum-Resistant Ovarian Cancer Treatment: Emerging Strategies and Market Dynamics
The platinum-resistant ovarian cancer treatment market is expanding with innovative therapies aimed at addressing unmet patient needs, promising better outcomes for patients.
third-news.com
October 9, 2025 at 9:43 PM
Strengthening the Future of Platinum-Resistant Ovarian Cancer Treatment: Emerging Strategies and Market Dynamics#United_States#Las_Vegas#Clinical_Trials#targeted_therapies#Ovarian_Cancer
GSK 3 Inhibitor Market Thrives with Renewed Focus on Targeted Therapies and Innovative Approaches#None#DelveInsight#targeted_therapies#GSK_3_Inhibitors
GSK 3 Inhibitor Market Thrives with Renewed Focus on Targeted Therapies and Innovative Approaches
The GSK 3 inhibitor market is poised for rapid growth, driven by new targeted therapies and clinical advancements promising significant change in treatment paradigms.
third-news.com
August 28, 2025 at 9:38 PM
GSK 3 Inhibitor Market Thrives with Renewed Focus on Targeted Therapies and Innovative Approaches#None#DelveInsight#targeted_therapies#GSK_3_Inhibitors
IDEAYA Biosciences to Showcase Innovations at July 2025 Investor Relations Event#United_States#Investor_Relations#IDEAYA_Biosciences#South_San_Francisco#targeted_therapies
IDEAYA Biosciences to Showcase Innovations at July 2025 Investor Relations Event
IDEAYA Biosciences is set to participate in a key investor relations event in July 2025, demonstrating its commitment to precision oncology and targeted therapies.
third-news.com
July 21, 2025 at 10:11 AM
IDEAYA Biosciences to Showcase Innovations at July 2025 Investor Relations Event#United_States#Investor_Relations#IDEAYA_Biosciences#South_San_Francisco#targeted_therapies
Follicular Lymphoma Market Insights: Forecasting Growth Trends and Key Advancements in Treatment Options#USA#Las_Vegas#Follicular_Lymphoma#targeted_therapies#Healthcare_Developments
Follicular Lymphoma Market Insights: Forecasting Growth Trends and Key Advancements in Treatment Options
The follicular lymphoma market is expected to grow significantly due to rising awareness, advancements in targeted therapies, and increased clinical trials throughout 2025-2034.
third-news.com
June 4, 2025 at 9:41 PM
Follicular Lymphoma Market Insights: Forecasting Growth Trends and Key Advancements in Treatment Options#USA#Las_Vegas#Follicular_Lymphoma#targeted_therapies#Healthcare_Developments
Dr. Owen Witte Honored with Prestigious Harrington Prize for Innovation in Medicine#United_States#Cleveland#targeted_therapies#Owen_Witte#Harrington_Prize
Dr. Owen Witte Honored with Prestigious Harrington Prize for Innovation in Medicine
Dr. Owen Witte has been awarded the 2025 Harrington Prize for Innovation in Medicine for his transformative work in targeted cancer therapies.
third-news.com
March 19, 2025 at 1:30 PM
Dr. Owen Witte Honored with Prestigious Harrington Prize for Innovation in Medicine#United_States#Cleveland#targeted_therapies#Owen_Witte#Harrington_Prize
Rgenta Therapeutics Enters Strategic Collaboration with GSK for RNA-Targeted Therapies#United_States#GSK#Rgenta_Therapeutics#RNA-Targeted_Therapies#Woburn
Rgenta Therapeutics Enters Strategic Collaboration with GSK for RNA-Targeted Therapies
Rgenta Therapeutics and GSK form a strategic alliance to develop novel RNA-targeted small molecule splice modulators for various diseases.
third-news.com
December 4, 2024 at 1:25 PM
Rgenta Therapeutics Enters Strategic Collaboration with GSK for RNA-Targeted Therapies#United_States#GSK#Rgenta_Therapeutics#RNA-Targeted_Therapies#Woburn
IDEAYA Biosciences to Engage in Major Investor Relations Events in December 2024#USA#oncology#IDEAYA_Biosciences#South_San_Francisco#targeted_therapies
IDEAYA Biosciences to Engage in Major Investor Relations Events in December 2024
IDEAYA Biosciences, a leader in precision medicine oncology, announces participation in key investor relations events in December 2024, highlighting its targeted therapies.
third-news.com
December 2, 2024 at 11:11 AM
IDEAYA Biosciences to Engage in Major Investor Relations Events in December 2024#USA#oncology#IDEAYA_Biosciences#South_San_Francisco#targeted_therapies